Aakash Desai: Here are the top 5 abstracts you don’t want to miss from ASCO24
Aakash Desai, Assistant Professor at O’Neal Comprehensive Cancer Center at UAB, shared a post on LinkedIn:
“Exciting updates coming at ASCO24, seems more like ASCOLung24, featuring two plenary sessions!
IMHO, Here are the top 5 abstracts you don’t want to miss:
HARMONi-A: Ivonescimab + chemo in EGFRm non-sq NSCLC post-EGFR TKI. #8508 Zhang et al.
EGFR-m NSCLC, 2L
Insightful findings on the role of this bispecific with ongoing HARMONi study!
PALOMA-3: A subcutaneous bispecific! SC vs IV amivantamab + lazertinib in refractory EGFR-mut NSCLC. LBA8505 Leighl et al.
Reduced infusion reactions and improved logistics!
NRG-LU002: Bringing the energy!
Maint sys tx vs. LCT + maint sys tx for limited met NSCLC. 8506 Iyengar et al.
Setting: Limited metastatic NSCLC
Endpoint: PFS/OS
Expanding options for oligomet NSCLC
ADRIATIC: Durvalumab as consolidation tx for LS-SCLC. hLBA5 David R. Spigel
Setting: LS-SCLC
Endpoint: PFS
Introducing IO in LS-SCLC, could it be practice changing? Awaiting full data…
LAURA: Osimertinib post-CRT in unresectable stage III EGFRm NSCLC. LBA4 Suresh S. Ramalingam, MD Unresectable stage III EGFRm NSCLC
Endpoint: PFS.”
Source: Aakash Desai/LinkedIn